7 Most Profitable Biotech Stocks To Buy Right Now

2. United Therapeutics Corporation (NASDAQ:UTHR

Latest Net Income: $1.20 billion  

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company specializing in treatments for rare and life-threatening diseases, primarily pulmonary arterial hypertension (PAH) and cardiovascular disorders.  Its main drugs, Tyvaso, Orenitram, and Remodulin, are marketed to patients, hospitals, and specialized pharmacies.

In 2024, United Therapeutics Corporation (NASDAQ:UTHR) exceeded forecasts with record revenue and robust earnings. The business exceeded forecasts of $6.10 with earnings per share (EPS) of $6.19. The financial performance was aided by double-digit growth in important drugs such as Unituxin, Tyvaso, Remodulin, and Orenitram.

United Therapeutics Corporation (NASDAQ:UTHR)’s Tyvaso revenue grew 19% year-over-year to $4 million in Q4, while Orenitram saw a 28% increase to $108 million. Remodulin saw a 17% increase in global sales of $135 million, while Unituxin saw a 25% increase in sales, reaching a record $68 million. These profits demonstrate how well-positioned the company is in the market for treating rare disorders like pulmonary arterial hypertension (PAH).

United Therapeutics Corporation (NASDAQ:UTHR) improved its clinical pipeline in addition to growing financially. The first FDA-approved xenotransplantation trial for organ replacement was the uKidney clinical trial, for which the business obtained IND permission. Confidence in long-term growth and innovation is strengthened by capital allocation that is balanced between strategic investments, acquisitions, and shareholder returns through repurchase plans.